122 related articles for article (PubMed ID: 23295643)
41. Tenofovir alafenamide for HIV infection: is less more?
Wyatt C; Baeten JM
Lancet; 2015 Jun; 385(9987):2559-60. PubMed ID: 25890672
[No Abstract] [Full Text] [Related]
42. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Greig SL; Deeks ED
Drugs; 2016 Jun; 76(9):957-68. PubMed ID: 27189707
[TBL] [Abstract][Full Text] [Related]
43. Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.
Ocque AJ; Hagler CE; Morse GD; Letendre SL; Ma Q
J Pharm Biomed Anal; 2018 Jul; 156():163-169. PubMed ID: 29709783
[TBL] [Abstract][Full Text] [Related]
44. FDA paves the way for pre-exposure HIV prophylaxis.
Holmes D
Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
[No Abstract] [Full Text] [Related]
45. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
[TBL] [Abstract][Full Text] [Related]
46. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
[TBL] [Abstract][Full Text] [Related]
47. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
Frampton JE; Croom KF
Drugs; 2006; 66(11):1501-12; discussion 1513-4. PubMed ID: 16906786
[TBL] [Abstract][Full Text] [Related]
48. Single-tablet, once-daily treatment regimens for HIV.
Sawyer JR; Ma Q; Hsiao CB
Lancet Infect Dis; 2014 Apr; 14(4):265-7. PubMed ID: 24670622
[No Abstract] [Full Text] [Related]
49. Genvoya--a new 4-drug combination for HIV.
Med Lett Drugs Ther; 2016 Feb; 58(1488):19-21. PubMed ID: 26859659
[No Abstract] [Full Text] [Related]
50. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
[TBL] [Abstract][Full Text] [Related]
51. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.
Temesgen Z
Drugs Today (Barc); 2012 Dec; 48(12):765-71. PubMed ID: 23243633
[TBL] [Abstract][Full Text] [Related]
52. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Schrijvers R; Debyser Z
Expert Opin Pharmacother; 2012 Sep; 13(13):1969-83. PubMed ID: 22849516
[TBL] [Abstract][Full Text] [Related]
53. FDA notifications. FDA approves generic combination of efavirenz, lamivudine & tenofovir.
AIDS Alert; 2009 Nov; 24(11):130. PubMed ID: 19960612
[No Abstract] [Full Text] [Related]
54. Antiretroviral rounds. Is that "one pill" treatment enough?
Gallant JE; Arribas JR
AIDS Clin Care; 2008 Jul; 20(7):53-4. PubMed ID: 18724479
[No Abstract] [Full Text] [Related]
55. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
56. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
57. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
Feng HP; Guo Z; Fandozzi C; Panebianco D; Caro L; Wolford D; Dreyer DP; Valesky R; Martinho M; Rizk ML; Iwamoto M; Yeh WW
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):952-961. PubMed ID: 31173673
[TBL] [Abstract][Full Text] [Related]
59. Skeletal muscle toxicity associated with emtricitabine/rilpivirine/tenofovir fixed-dose combination: a case report.
Nguyen LB; Harent S; Peytavin G; Visseaux B; Bastard JP; Dubourg O; Lariven S; Patrick Yeni ; Yazdanpanah Y; Lescure FX
AIDS; 2014 Aug; 28(13):1995-7. PubMed ID: 25259710
[No Abstract] [Full Text] [Related]
60. Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A; Leal L; González E; León A; Lucero C; Mallolas J; Torres B; Laguno M; Rojas J; Martínez-Rebollar M; González-Cordón A; Cruceta A; Arnaiz JA; Gatell JM; García F;
J Antimicrob Chemother; 2017 Oct; 72(10):2857-2861. PubMed ID: 29091217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]